Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $43 | In Stock | |
10 mg | $61 | In Stock | |
25 mg | $93 | In Stock | |
50 mg | $126 | In Stock | |
100 mg | $207 | In Stock | |
500 mg | $515 | In Stock | |
1 mL x 10 mM (in DMSO) | $48 | In Stock |
Description | Ixazomib citrate (MLN9708) is a prodrug of Ixazomib (MLN-2238) and an orally bioavailable second-generation proteasome inhibitor with an IC50 of 3.4 nM, exhibiting potential antineoplastic activity. |
Targets&IC50 | 20S proteasome β1:31 nM , 20S proteasome β5:3.4 nM , 20S proteasome β2:3500 nM |
In vitro | Treatment of MM cells with MLN2238 predominantly inhibits chymotrypsin-like activity of the proteasome and induces accumulation of ubiquitinated proteins. MLN2238 inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies without affecting the viability of normal cells[1]. |
In vivo | In animal tumor model studies, Ixazomib is well tolerated and inhibits tumor growth with significantly reduced tumor recurrence. A head-to-head analysis of Ixazomib versus bortezomib showed a significantly longer survival time in mice treated with Ixazomib than mice receiving bortezomib[1]. |
Alias | MLN9708 |
Molecular Weight | 517.12 |
Formula | C20H23BCl2N2O9 |
Cas No. | 1239908-20-3 |
Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (193.38 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.